Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Journal of Skin and Stem Cell
  4. Articles

  5. Serum Level of Insulin-Like Growth Factor 1 in Patients with Acne Vulgaris Versus Healthy Subjects
  6. Scopus by Title (Ref)

Journal of Skin and Stem Cell

The Official Journal of Skin and Stem Cell Research Center

Home
Current IssueAll IssuesIn PressSearchAccepted Manuscripts
Instructions
Journal InformationBoards and CommitteesIndexing and Listing SourcesPublication Ethics and Malpractice StatementSupportReviewer and AE Registration FormJournal MetricsContact UsOpen Peer Review (OPR)
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. Regulatory roles of transcription factors and receptors in the pathogenesis of acne

- Feng M. , et al.

2. The potential role of insulin-like growth factor 1 in acne vulgaris and its correlation with the clinical response before and after treatment with metformin

- Albalat W. , et al.

3. Metformin in skin diseases

- Kadylak D. , et al.

4. The insulin-like growth factor-1 (G>A) and 5,10-methylenetetrahydrofolate reductase (C677T) gene variants and the serum levels of insulin-like growth factor-1, insulin, and homeostasis model assessment in patients with acne vulgaris

- Zinati-Saeed S. , et al.

HomeInstructions

Articles

  • Current Issue
  • All Issues
  • In Press
  • Search
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Boards and Committees
  • Indexing and Listing Sources
  • Publication Ethics and Malpractice Statement
  • Support
  • Reviewer and AE Registration Form
  • Journal Metrics
  • Contact Us
  • Open Peer Review (OPR)
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.